Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 936-937

  Benedetti, Giovanni ^a,d   Latini, Luciano ^b   Galetta, Domenico ^b   Colucci, Giuseppe ^a   Crinò, Lucio ^c  

^a Hospital of Macerata   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d Ospedale di Macerata   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER;

ADULT; ANAPHYLAXIS; ASPIRATION BIOPSY; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG PENETRATION; DRUG WITHDRAWAL; EXON 19 DELETION; FATALITY; FEMALE; FOLLOW UP; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HEMIPLEGIA; HUMAN; LARGE CELL CARCINOMA; LETTER; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE INTRACRANIAL METASTASIS; PRIORITY JOURNAL; RASH; SPLEEN; TRANSBRONCHIAL BIOPSY; TREATMENT DURATION; TUMOR VOLUME; WHOLE BODY IMAGING;

EID: 68549096320     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a9a0a2     Document Type: Letter

References (5)

1. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: A review. Ann Oncol 1999;10:753-759. (Pubitemid 29367990)
2. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in nonsmall- cell lung cancer. J Clin Oncol 2007;25: 587-595. (Pubitemid 350002967)
3. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006;24:369s (suppl; abstract 7020).
4. Fekrazad MH, Ravindranathan M, Jones DV Jr. Response of intracranial metastases to erlotinib therapy. J Clin Oncol 2007;25:5024-5026. (Pubitemid 350220437)
5. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 2008;3:832-839